Market Segmentation Drug Class Insights (Revenue, USD Bn, 2021 - 2033) Exenatide Liraglutide Dulaglutide Lixisenatide Albiglutide Semaglutide Route of Administration Insights (Revenue, USD Bn, 2021 - 2033) Parenteral Oral Application Insights (Revenue, USD Bn, 2021 - 2033) Type 2 Diabetes Mellitus Obesity Liver Cirrhosis Non-alcoholic Steatohepatitis Others Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) Hospital Pharmacies Retail Pharmacies Online Pharmacies Regional Insights (Revenue, USD Bn, 2021 - 2033) North America U.S
Some patients take GLP-1s for a shorter time to jumpstart their weight loss, while others may benefit from extending their treatments to help improve health conditions or for continued weight management support
Abstract Obesity is a complex disease characterized by excessive fat accumulation which is caused by genetic, environmental and other factors
FDA guidance on compounding continues evolving
They also delay aging , reduce free radical damage, and increase overall vitality